Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.50 |
| ▸ | PPARA | Q07869 | 12/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648557 | 0.86 | PPARG (0.47) | PPARGPPARAACP3CYP2C9CYP2C19 | |
| SCHEMBL2648458 | 0.83 | MME (0.50) | METAP2METAP1ALDH1A1 | |
| SCHEMBL2648456 | 0.83 | MME (0.50) | METAP2METAP1ALDH1A1 | |
| SCHEMBL6597500 | 0.82 | METAP2 (0.42) | PPARGPPARAACP3HDAC8HDAC6 | |
| SCHEMBL2647943 | 0.82 | PPARG (0.42) | PPARGPPARAACP3HDAC8HDAC6 | |
| SCHEMBL2647309 | 0.80 | KCNH2 (0.43) | PPARGPPARAMETAP2METAP1 | |
| SCHEMBL1418773 | 0.80 | CYP2C19 (0.47) | CYP2C19METAP2METAP1 | |
| SCHEMBL1418768 | 0.80 | CYP2C19 (0.47) | CYP2C19METAP2METAP1 | |
| SCHEMBL2647453 | 0.79 | GCK (0.46) | PPARGPPARAHDAC8HDAC6 | |
| SCHEMBL2647663 | 0.78 | GCK (0.62) | CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282611-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| EP-1282611-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| US-6384220-B2 | ANTIDIABETIC AGENTS INCREASING THE EXPRESSION OF GLUCOKINASE (GK) TO IMPROVE GLUCOSE TOLERANCE; INCREASE IN GLUCOSE EXPOSURE COUPLED THROUGH GK IN BETA-CELLS TO INCREASE INSULIN SECRETION AND IN HEPATOCYTES TO INCREASE GLYCOGEN DEPOSITION | HOFFMANN-LA ROCHE INC. | 2002-05-07 | — | — | US | disclosed |
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | HOFFMANN-LA ROCHE INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | GCKR, GCK, PDXK | PPARG 78/4885PPARA 168/4885ACP3 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.